Vinyl chloride: still a cause for concern. by Kielhorn, J et al.
RESEX
Vinyl Chloride: Still a Cause for Concern
JanetKielhorn,1 Christine Melber,1 Ulrich Wahnschaffe,1 Antero Aitio,2 andInge Mangelsdorf'
1Fraunhofer Institute for Toxicology and Aerosol Research with Drug Research and Clinical Inhalation, Hanover, Germany;
2lnternational Programme on Chemical Safety, World Health Organization, Geneva, Switzerland
Vinyl chloride (VC) is both a known carcinogen and a regulated chemical, and its production
capacity has almost doubled over the ltst 20 years, currently 27 million tons/year woddwide.
According to recent reports it is still a cause for concern. VC has been found as degradaton
product ofchloroethylene soIvents (perchloroethylene and trichloroethylene) and in landfill gas
and groundwater at concentrations up to 200 mg/m3 and 10 mg/L, respectively. Worldwide
occupational eposure to VC still seems to be high in some countries (e.g., avernges ofapproxi-
mately 1,300 mg/m3 until 1987 in one fory), and exposure may also be high in others where
VC is not regulated. By combining the most relevant epidemiologic studies from several coun-
tries, we observed a 5-fold excess ofliver cancer, primarily because ofa 45-fold excess risk from
ngiosarcoma of the liver (ASL). The number ofASL cases reported up to the end of 1998 was
197worldwide. Theeaveage latencyforASLis22years. Somestudies showasmall excess riskfor
hepatocellular carcinoma, and others suggest a possible risk of brain tumors among highly
exposedworkers. Lungcaner, lymphomas, or leukemiado notseemto berelated toVCexposure
according to recent results. The mutation spectra observed in rat and human liver tumors (ASL
and/or hpatoceflularcarcinoma) that are associatedwith expomre to VC are dearlydistinct from
those observed in sporadic liver tumors or hepatic tumors that are associated with other expo-
sures. In rats, the substitution mutations found at A:T base pairs in the .ras and p53 genes are
consistent with the promutagenic properties ofthe DNA adduct 1,J'-ethenoadenine formed
from VC metabolites. Risk assessments derived from animal studies seem to overestimate the
actual riskofcancerwhencomparingestimated and reported cases ofASL. Keywor&h: angiosarco-
ma ofthe liver (ASL), landfill leachate, liver cancer, occupational exposure, risk assessment, vinyl
chloride. EnvironHealb Pcrspect108:579-588 (2000). [Online 2June2000]
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Vinyl chloride (VC) is one of the best-stud-
ied chemicals. Because of evidence that VC
was carcinogenic in both animal studies and
in human case reports in the early 1970s,
there were drastic changes in the production
methods and in occupational hygiene in the
VC/polyvinyl chloride (PVC) industry in the
Western World, with the closure ofsome fac-
tories that were not able to conform to the
strict regulations and occupational exposure
limits. VC levels in PVC resins and products
were also restricted. As a result of the strict
occupational exposure limits, no cases of
angiosarcoma of the liver (ASL), the rare
tumor associated with VC exposure, have
been reported in newworkers exposed to VC
in those factories since that time. It seemed
that the VC problem had been solved and
the story committed to the toxicologic histo-
ry books. But recent epidemiologic, environ-
mental, and biomechanistic findings have
opened up new aspects ofthis chemical. VC
has recently been evaluated by an interna-
tional interdisciplinary task group; this
paper highlights these recent developments,
which are presented in more detail in the
International Programme on Chemical
Safety (IPCS) Environmental Health Criteria
document on VC (1). VC remains a cause
for concern because potential exposure to
this chemical and new cases ofASL are still
being reported.
Historical Background
VC was first used commercially in the
1920s, but it was not until the 1930s that
techniques were devised to polymerize VC
into stable forms of PVC. Polymerization is
a batch process and takes place in a reactor
(autoclave) under controlled conditions.
Once the polymerization has ended, VC is
emptied into degassing tanks. The reactor has
to be cleaned periodically because a film of
PVC forms on the inside wall ofthe reactor.
Although this is now performed with solvents
or automatic high-pressure jets, previously
this task was a manual process requiring
workers to use spatulas or hammers and chis-
els; the workers were exposed to high concen-
trations of VC up to 1,000 ppm (2,600
mg/m3) and possibly even higher peaks of
exposure. As a result, some of these workers
suffered from a specific pathologic syndrome
called "vinyl chloride disease," with symptoms
including earache and headache, dizziness,
unclear vision, fatigue and lack of appetite,
nausea, sleeplessness, breathlessness, stom-
achache, pain in the liver/spleen area, pain
and tingling sensation in the arms/legs, cold
sensation at the extremities, loss oflibido, and
weight loss (2). Clinical findings included
scleroderma-like changes in the fingers, with
subsequent bony changes in the tips of the
fingers described as acro-osteolysis; peripheral
circulatory changes similar to Raynaud's phe-
nomenon; and enlargement of the liver and
spleen, with a specific histologic appearance
and respiratory manifestations (3-6).
After the case series on hepatic angiosar-
coma among workers exposed to vinyl chlo-
ride (2) was published in 1974, several further
case series and small epidemiologic studies,
primarily with emphasis on hepatic tumors,
were published in the 1970s and 1980s
(8-28). These reports showed that exposure
to high levels ofVC were associated with the
incidence ofASL. Other (non-ASL) cancer
sites and types that may be connected with
VC exposure include tumors ofthe liver (e.g.,
non-angiosarcoma), particularly hepatocellular
carcinoma; respiratorysystem; digestive system
other than the liver; lymphopoietic and
hematopoietic tissue; brain and other central
nervoussystem; and malignantmelanoma.
Parallel to human case reports, after the
first reports of the carcinogenicity ofVC in
rats (29,30), extensive studies were carried out
in the rat, mouse, and hamster on the effects
oforal (31-33) and inhalation (3432) expo-
sure to VC. These studies have shown that
VC is both genotoxic and carcinogenic,
causing a wide spectrum oftumors in various
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animal species. Tumors that have been been
found, at least in animal species, indude ASL
and other livertumors, mammarygland carci-
noma, neuroblastoma, nephroblastoma,
forestomach and lung tumors, and Zymbal
gland tumor. Non-neoplastic effects include
reduced body weight and increased relative
spleen weight, hepatocellular degeneration,
proliferation ofcells lining the liver sinusoids,
degenerative alteration in the testis, tubular
nephrosis, and focal degeneration of the
myocardium in rats (38,39).
New Aspects of VC
Production
VC has a world capacity ofabout 27 million
tons/year worldwide, almost double the pro-
duction in 1980 (Table 1), and is produced in
most industrial countries. Five percent ofthis
VC goes into the production of chlorinated
solvents, primarily 1,1,1-trichloroethane
(10,000 tons/year). Most (95%) VC pro-
duced is further polymerized under varying
conditions toproduce PVC.
VC Environmental Contamination
and Remediation
Reports from several countries (43-59)
recently showed high levels ofVC contami-
nation in soil, groundwater, aquifers, and
wells near landfill and industrial waste
disposal sites that were not located near
VC/PVC production facilities. VC concentra-
tions were up to 12 mg/L in some groundwa-
ter samples and up to 230 mg/m3 in landfill
gas samples (Table 2). VC can be formed
microbially, under anaerobic conditions,
from the reductive dehalogenation of the
more highly chlorinated chloroethenes: per-
chloroethylene (PCE), trichloroethene
(TCE), and the dichloroethene isomers,
cis-1,2-dichloroethene (cis-1,2-DCE),
trans-1,2-DCE, and 1,1-DCE (Figure 1)
(59-62). PCE and TCE are used as industri-
al solvents for degreasing and cleaning metal
parts and electronic components and in dry
cleaning. Careless handling, storage, and dis-
posal, as well as the high chemical stability of
these compounds, have made them, and con-
sequently VC, some of the most frequently
encountered groundwater contaminants.
Although VC may be further degraded to less
and nonchlorinated ethenes and possibly
finally to carbon dioxide and ethane, this
proceeds at a slow rate under highly reducing
conditions (63-65); as a consequence, there
can be a build-up ofVC in landfills and sur-
rounding areas.
Several field studies of PCE/TCE-conta-
minated landfill sites and aquifers (61,66-70)
have shown that, under specific conditions,
PCE andTCE can be intrinsically biodegrad-
ed anaerobically to ethene by indigeneous
methanogenic, acetogenic, and sulphate-
reducing bacteria. Also, under aerobic
conditions there is a potential for direct or
cometabolic oxidation of DCE and VC.
Because each site has individual conditions
(e.g., the presence ofother solvents such as
acetone and methanol), the degradation rates
cannot be directly compared. In one study,
half-lives of 1-2 years have been estimated
for each stage in the reaction chain (e.g.,
DCE to VC; VC to ethene) (49). In general,
except underspecificconditions, there is little
biodegradation ofVC.
The awareness ofthis problem ofVC for-
mation has encouraged the development of
in situ bioremediation ofchlorinated solvents
and VC using anaerobic or aerobic cometa-
bolic processes (72-74).
Several laboratories are now attempting
to isolate strains of bacteria that can com-
pletely dehalogenate cis-DCE or VC to
ethene. Although no known microorganism
Table 1.World PVCa production/capacity 1980-1998.
Production/capacity in 1,000tons/year
Region 1980b 1985b 199ob 1995C 1998d
World capacity 16,000 17,000 20,700 26,400 -27,000
Production 11,750 14,200 18,300
North America total 3,200 3,390 4,700 6,070
Suspension and mass 2,810 2,990
Vinyl acetate copolymer 200 210
Emulsion 190 190
Western Europe total 3,900 4,330 4,800 5,750 - 5,600
Suspension and mass 33,350 3,700
Vinyl acetate copolymer 130 130
Emulsion 420 500
Eastern Europe 925 1,100 1,200 2,700e
Soviet Union 370 700 760
Japan 1,400 1,550 2,070 8,200f
Southeastern Asia 330 600 900
People's Republic of China 150 400 790
South America 400 540 780
Rest ofWorld 1,075 1,590 2,300 3,680
"Approximate VC production/capacity. 1bDatafrom Allsopp and Vianello(40h. CDatafrom Rehm and Werner(41). dPersonal
communication, European Council ofVinyl Manufacturers (421. &Including the former Soviet Union.1rotal forAsia.
can aerobically destroy PCE, some anaerobic
bacteria (e.g., Dehalobacter restrictus) use
these chlorinated solvents as electron accep-
tors for energy conservation and growth
(dehalorespiration), by breaking them down
in the process to form cis-dichloroethene,
although restricted diet and conditions are
necessary (75,76). A coccoid bacterium
has been isolated (provisionally named
Dehalococcoides ethenogenes strain 195) that,
together with extracts from mixed microbial
cultures, can dechlorinate PCE to form cis-
DCE and remove other chlorine atoms to
form vinyl chloride and finally ethene (77).
Meier (78) reported that quantitative miner-
alization of VC was possible with isolated
aerobic cultures of Mycobacterium aurum
underspecial conditions.
General Population Exposure
Exposure of the general population to VC is
possible by several routes: inhalation of air
polluted with VC, mainly in the vicinity of
VC/PVC plants orwaste disposal sites; intake
ofcontaminated drinking water; ingestion of
food, beverages, and medicaments packed in
PVC; and absorption through skin from
PVC-wrapped cosmetics. Normally, the gen-
eral population is exposed, if at all, to only
small amounts ofVC. However, the exposure
varies depending on the regulatory measures
ofeach country, the occurrence ofaccidents,
or thespreadofprecursorsubstances.
After an accident in Schonebeck,
Germany, inJune 1996, which involved the
derailment of a train carrying VC and the
subsequent fire, 325 persons were docu-
mented as having acute symptoms, but these
correlated with exposure to the pyrolytic
products (e.g., hydrochloric acid) and not to
VC itself. Over 1,000 tons of VC were
involved, of which approximately 250 tons
burned and 350 tons were reclaimed after
the fire. One hundred fifty tons ofHCI were
released (79). According to measurements
first taken 14 hr after the fire, the maximum
concentrations ofVC were approximately 80
mg/m3 near the train and 25 mg/m3 at 200
m from the center ofthe fire (80). In a study
of 29 individuals exposed as a result of this
accident, there was a significant increase in
chromosomal abberrations as compared to
an unexposed control group (81).
With the improvement in industrial
hygiene and stricter emission controls in
many countries, the general population is
not usually exposed to emissions from VC
and PVC production facilities, but there are
exceptions. For example, Zhao et al. (82)
reported that, in China, workers and their
families were exposed to VC because the
dormitories were near or even on the campus
of the PVC/VC plant. In 1988, maximum
and mean daily concentrations of 12.7 and
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4.4 mg/m3, respectively were measured in
dormitories 50 m away from the plant (82).
Occupational Exposure Levels
Industrial environments associated with VC
exposure include VC production plants, VC
polymerization (PVC production) plants,
and PVC processing factories. For example,
the number of workers exposed to VC has
been estimated to be approximately 80,000
in the United States (1981-1983) (83) and
> 5,000 in Sweden (1975-1980) (84).
Because VC was not recognized as a toxic
compound at the beginning ofVC/PVC pro-
duction in the United States and Western
Europe, no precautions were taken against
contact and no regular workplace monitoring
was performed. Therefore, only sporadic
measurements or retrospective estimates of
exposures are available for the period before
1975 (Table 3). Some VC workers, autoclave
cleaners in particular, were estimated to be
exposed to as much as 1,000 ppm (2,600
mg/m3) in the 1950s and earlier (85-89).
The exposure was reduced to one-tenth of
this by the mid-1970s. After 1975, levels were
usually < 1-5 ppm (< 2.6-13 mg/m3) in
many countries.
In many countries, factories that could
not reduce the emissions ofVC to satisfy the
rigorous laws in the early 1970s were forced
to close. In other countries, this was not
possible for socioeconomic reasons; thus,
large factories with old-fashioned technolo-
gies continued the manufacturing process
(90) and workers continued to be exposed to
high levels ofVC (Table 4).
Recent data from Croatia may reflect the
actual conditions still prevalent in some
countries. A retrospective investigation of
the exposure to VC has been performed in
37 autoclave workers in Split, Croatia, who
were maximally exposed to the emission of
VC by the nature oftheirjob (emptying and
cleaning) in a suspension polymerization
plant. The investigation covered the period
from 1969 to 1987, after which the factory
was closed due to the high emission ofVC.
Data show that the 37 workers were exposed
over this period to average VC concentrations
of approximately 500 ppm (1,300 mg/mi3)
(90,92). As a consequence ofthis high expo-
sure to VC, a disproportionately large num-
ber ofASL mortalities have been reported in
Croatia (Table 5).
Angiosarcoma ofthe Liver
ASL, also known as hemangioendothelial
sarcoma, is an extremely rare liver tumor and
is difficult to diagnose. ASL constitutes only
2% ofall primary tumors of the liver in the
general population; for example, from
1975-1987 figures in England and Wales,
there was an annual incidence of 1.4 cases/10
million people (101). ASL has been associat-
ed only with exposure to VC, Thorotrast (a
Table 2 Vinyl chloride found in landfilVwaste disposal sites as a gas, in leachate, and in groundwater
formed probablyfrom degradaton ofhigherchloroethenes.
Measure Concentrations Reference
Maximumr
Average 34.M4M3
(45)
(.46
(4;,)
Industrial landfill; 41 mg/n3;
Municipal lanffill 10m 3
G ..
!.....i°..,..................... i °.. .
Landfiillgas Unit iingtkinm 7 wastedisposal Range <0.1-7 mg/m3 (49)
sites
atr 'ersany, untwAs . .. a ...
Leachate Wisconsin: municipal solidwase Range 1jgL (5?)
site(1982)
....
Groundwater Germany, contaminated water Range
Range
&94SO g/L
<540pg/L
15-1,000
u/L
.( ... -;
(54) >gr,.
(.5. 6) '';'
Figure 1. Microbial degradation of chlorinated
ethenes to form vinyl chloride.
Table 3. Retrospective estimates of daily occupa-
tional exposures to vinyl chloride before 1975.
VC exposure
Country/period (mg/m3) References
Germany
"First years" >2,600 (85)
Before 1971 1,300
1971 260
1974 5.2-7.8
United Kingdom
1945-1955 2,600 (86-88)
1955-1960 1,040-1,300
1960-1970 780-1,040
Mid-1973 390
1975 13
United States
1945-1955 2,600 (89)
1955-1970 780-1,300
1970-1974 260-520
1975 < 2.6-13
Exposure levels during autoclave cleaning may
have been as high as 7,800 mg/m3 (86).
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contrast medium used in X-ray radiography
in the 1930s-1950s), and arsenic (7,102).
There are only afewinstances where the diag-
nosis of a rare tumor enables the identifica-
tion ofa risk without having to rely on large
epidemiologic studies. Furthermore, cases of
ASL in VC workers could be directly attrib-
utable to exposure to VC. Regular interna-
tional surveillance of cases ofASL from VC
exposure shows that 118 cases were registered
in 1985 (103), 173 in 1993 (104) and 197
up to the end of 1999 (105) (Table 5). The
average latent period between starting work
in an occupation involving VC exposure and
the ASL diagnosis or death for 99 cases was
22 years (87,106). Because ofthis long laten-
cy, tumors are still detected although the
exposure has ceased or has been considerably
reduced. ASL seems to be associated only
with high exposure to VC.
Abdominal pain, weakness, fatigue, and
weight loss are the most prominent clinical
symptoms, and hepatosplenomegaly, ascites,
and jaundice are the most common clinical
signs. Remarkably, except for the final
stages, there seems to be little impairment of
hepatic function in ASL patients (106). Any
treatment is generally unsuccessful, and sur-
vival after diagnosis usually averages < 12
months. Hepatic failure and intra-abdomi-
nal hemorrhage are the usual terminal effects
(104,107). Liver transplantation might be
the only chance of survival (108). Surgical
resection and adjuvant chemotherapy have
been suggested if ASL is detected early
enough (109-111).
Epidemiologic Studies on
VC/PVC Workers
From the data on health surveillance and
mortality records of VC workers and the
easy correlation ofASL with VC exposure,
there have been numerous case reports,
cohort studies, and epidemiologic studies on
VC/PVC workers from many countries. But
because there are only estimates of levels of
VC exposure before the mid-1970s, there are
not enough data in many cases to estimate
an exposure-response relationship.
Two larger studies combined earlier stud-
ies from the United States (112) and Europe
(113) and updated the mortality follow-up.
These studies have been or are currently
being updated again (114,115).
Wong et al. (112) updated earlier U.S.
studies (8,9) and subsumed others (10-15).
The cohort included 10,173 men who had
worked for at least 1 year in jobs involving
VC exposure in 37 plants in the United
States before January 1973. The observation
covered 1942-1982, and the authors com-
pared the observed mortality to the expected
rates, based on U.S. national rates for white
males, standardized for age, and calendar
time. In an attempt to characterize historical
exposures, Wong et al. (I11) graded individ-
ual jobs and job locations by each company
as "high," "medium," or "low"; this approach
failed because ofdifferences ofinterpretation
ofthe terms into parts-per-million levels. The
actual levels ofexposure are not known.
The second large cohort study, by
Simonato et al. (113), updated several earlier
European cohorts (16-22,96), and comprised
a total of 14,351 subjects from 19 factories.
After exclusion ofshort-term employees (< 1
year), females, deaths outside the observation
period, and members of more than one
cohort, 12,706 subjects remained for the
analysis. The follow-up was 97.7% complete,
and the average length of follow-up was 17
years, giving a total number of222,746 per-
son-years. National rates ofmortality, specific
for age and 5-year calendar periods were used
Table4. Occupational ezposur: reported levelsofvinyl chlorde inworkplaceair samples inVC/PVC pro-
ductionplants.
Concentrations -:
Country Workplace Year reportedR(mgglm3 Refence
China P/Cpoduionplant Notspecified 30-210
Croatia C/PiVGplat 1949-1987 Mean=54ocsioat Sakds {9t,9
Finland /tsproictionpjant, 1981-1985 c0.3-S7
breathingzone 1986-1989 <0.3-46
conenttions (TWA 1993 <0.3-26
al ,; .O-498. ....... Poland - a .. 1 Y/4Geometric mean=9`(Y71
(audlecleaners) 1982 9-180
tf,5-.E.-....... ..., ......
16Probes{(wholeplant) 1990-1993
Underthe.reactor 1990-1993
Incomemsor room 1990-1993
Rangeofannual means=1-9
Rangeofannualmeans= S201
Abbreviations: ND, notdetermined; TWA,time-weighted average. *1 ppm = 2.6mg/mi3.
Table 5. Number ofvinyl chloride-associated ASL cases reported per country.
Casesto 1999
Country Cases to 1985a Casesto 1993b (changes since 1993)c
United States 35 44 50(+6)
Germany 26 (West) 41 40(-1)
France 18 28 31 (+3)
United Kingdom 9 20 21 (+1)
Canada 10 13 13
Croatia 4 4 12 (+8)
Slovakia 2 2 6(+4)
Italy 4 8 8
Sweden 5 5 5
Japan 2 3 41+1)
Belgium 2 2 2
Norway 1 1 1
Spain 1 1
Australia 1 1
Brazil 1 (+1)
Israel 1 (+1)
Totald 118 173 197
&From Forman et al. (1031. bFrom Lee et al. (7104). cAssociation of Plastics Manufacturers in Europe (105). dThere is no
information regarding ASL cases from several countries known to be producers of PVC, and some plants have con-
tributed disproportionately tothe total.
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for the comparison. The observation period
was different for different factories. In most
cases, the observation period began in 1955
and extended to 1986. Calendar period-spe-
cific job exposure matrices were developed
for 13 ofthe 19 factories. These job exposure
matrices were developed using the job title as
basic unit in which exposure was assessed.
Estimates of exposure were assigned a priori
by a group of industrial hygienists on the
basis of the historical information available
from the companies.
Four smaller prospective studies on VC
exposure workers have been conducted in
Canada (23), Germany (24,25), France
(26,27) and the former Soviet Union (28).
IPCS Task Group Findings
The IPCS Task Group (1) reported that
"there is a 5-fold excess risk for liver cancer
observed among workers exposed to V";
this occurs primarily in PVC polymerization
factories, where the highest exposures to VC
occur (Table 6). Much of the excess risk can
be attributed to the excess risk for ASL. In
the European study, Simonato et al. (113)
found a 45-fold excess risk for ASL in work-
ers exposed to VC > 10,000 ppm-years as
compared to workers exposed to < 2,000
ppm-years (Table 7). In the European study,
there was histopathologic confirmation of
type ofliver cancer for 17 out of24 liver can-
cers; ofthose confirmed, 16 wereASL. In the
U.S. study, Wong et al. (112) registered 21
out of 37 liver cancer deaths as ASL. In the
Canadian study, Theriault and Allard (23)
reported that all 8 of the liver cancer deaths
were ASL; this was also the case for the 3
liver cancer deaths reported in the French
study by Laplanche et al. (27). There is no
information about whether liver cancers were
ASL in the German study by Weber et al.
(24), and in the Russian study, Smulevich
(28) reported no diagnosed liver cancers.
Some ASL cases in VC-exposed workers have
probably remained undiagnosed; the causes
of these deaths may have been recorded on
death certificates as unspecified liver cancers
or other liver-associated disease.
The risk for hepatocellular carcinoma
(HCC) was examined in several studies.
Simonato et al. (113), Theriault and Allard
(23), and Laplanche et al. (27) did not
observe an excess risk ofHCC, whereas data
from Wong et al. (112) in the United States
and from updates of the Italian component
of the European cohort (116,117) seem to
indicate that there is an excess risk for HCC.
The risk for HCC is not as great as the risk
for ASL. It is difficult to interpret the results
ofthese studies for HCC because ofthe pos-
sible inaccuracies ofdiagnoses ofangiosarco-
ma and HCC based on death certificate
information and because of the lack of
histopathologic confirmation of liver cancer
diagnoses. The IPCS Task Group (1) has
determined that "although the results are not
fully consistent between studies, the data
suggest that there may be a small excess risk
for HCC."
The IPCS Task Group (1) also reported
that
Four out offive studies reporting results for brain
tumours identified a moderate excess risk with [a
standard mortality ratio] of 1.42 for the com-
bined data from 5 studies (43 observed, 95% CI
[confidence interval], 1.03-1.91).
The risk for brain tumors tended to increase
with duration of exposure and employment
in the European (113) and U.S. (112) stud-
ies. Furthermore, in the U.S. study, Wong et
al. (112) reported that the highest risk
occurred in the two factories where the most
ASL cases had been diagnosed; these were the
factories where the highest VC exposure was
presumed to have occurred. In the European
T. Swsuuyr$flndi nbc smsfork auindo workeSin PVC.pefymerization pins .
All causes
Obs/Exp 1.438/1,636.4 1,536/1,705.27 414/434.7 5911.0 4043"
SMR O0 8.9 ' 5 3 ' 1.
cl tr ; ' (Z-O. (0.86-0.95) (0.61.5)
831:. 4X v Wi lAS d\l 13 07 442 ; S' ''1$t
Livercancr including A
Obs/Exp -24/8)1 -. 37/5.71 - ~12/01i9 0/n.a 8/0.14 3 81/19.21
SMR 2.86 6.41 15.2 57.14 3ASL 5.33
Cl (1.83-4.25)d (4.5-8.84r0 8ASLf. (423-6.82) @:rX';!~~~~~~~~~~~~~~~~~~~-C~......................
Lun. s
Obs/Exp 144/148.3 A1.11/115.87 24/26.6 1/1.2 2/5i.7B2 282/297.75
SMR 0.97 0.96 0.96 0.83 0.34 9
Cl (0.82-1.14) (0.79-1.18) (0.84-1.06}
20/P.? ' 7131* : 3 1 2 tv;.' . .. . .. m . .. .
Ob§/Exp 18/1 9,3h ~~24/21.8 5/1.2
SMR 0.93 1.1 4.17
|~~~1 wfiQ
r > |*);C~ DfSsv4;
,:.~ ~ ~ ~ ~~' ' :
Abbr iedo confidenc int Sxp o0b .ra ;o.
'Calculated bythe ICS Tsk GoupAhewncde studies etlaptache al (7, who do no provide Obsp vslues.PVles ownar, expseonexsed, relaive risk, and
Ct awsg pawtf'a l p*ib rsAt Thoetwe 15 ASL cases reaerded on death- tirtifcatesend 21 ASL cases
recorded in an internaonal register.t'us 2 undiagnosed ASI cases.#All respiratory neoplati Lkhwqoa and ae:ignant myelena.
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study in which the dose-response relation-
ship was examined, Simonato et al. (113)
observed no association ofbrain tumors with
cumulative exposure to VC. The overall epi-
demiologic evidence suggests a possible risk
for brain tumors among VCworkers.
An increase in lung cancer among VC
workers had been reported in some early
studies (10). However, there was no excess
risk indicated in the two largest studies-the
European (113) and U.S. (112) studies-or
in the other four smaller studies (23,24,
27,28). No associations were found for
either the duration ofexposure/employment
in the U.S. (112) or European (113) studies,
or for cumulative exposure to VC in the
European study (113).
An excess risk for malignant lymphomas
was reported in some early studies (10,14,
25,28), but no excess risk was observed in the
two largest cohorts [the U.S. (112) and
European studies (113)] or in the Canadian
cohort (23). In both the Russian (28) and
German (24) studies, an excess risk for
leukemia and lymphoma combined was
observed.It should be noted that different
methods of disease classification were used
and sometimes lymphomas were grouped
with malignant myelomas. The overall results
of these studies do not show any significant
increased risk for lymphomas or leukemia.
Since the IPCS Task Group meeting in
January 1999 in Hanover, Germany, the
update ofthe study by Wong et al. (112) has
been completed (114). Specific cancers that
showed meaningful excesses both through
1982 and through 1995 included cancers of
the liver and the biliary tract (mostly due to
a large excess of deaths due to ASL), the
brain, and the connective and soft tissues.
Of several causes of death previously
believed to be related to VC exposure, no
excesses were observed; these include lung
cancer, cancers oflymphatic and hematopoi-
etic tissue, emphysema and pneumoconioses,
and other lung diseases, including chronic
obstructive pulmonary disease.
VC Initiation ofHepatocarcinogenesis
Carcinogenesis is a multistep process. In the
last few years, progress has been made in the
understanding of a possible mechanism of
initiation of hepatocarcinogenesis by VC.
Recent studies (1,118-121) indicate that VC
acts as a genotoxic carcinogen. After metabol-
ic activation ofVC into chloroethylene oxide
(CEO) by cytochrome P450 isozyme 2E1
(CYP2E1), it exerts various genotoxic effects
(including gene mutations and chromosomal
aberrations) in different organisms, including
bacteria, yeasts, mammalian cells in culture,
Drosophila, rodents, and humans [reviewed
by Giri (122) and updated by the IPCS (1)].
Among the mutagenic events induced by
VC, base pair substitutions appear to be the
most frequent (118).
In vitro studies have demonstrated that
CEO and chloroacetaldehyde can alkylate
nucleic acid bases (Figure 2) (1,118,119,123).
7-(2'-Oxoethyl)guanine, the major DNA
adduct formed by VC and CEO, does not
exhibit promutagenic properties. In contrast,
four minoradducts, 1,M-ethenoadenine (-A),
3,N4-ethenocytosine (-C), N2,3-ethenogua-
nine (N2,3-sG), and 1,N2-ethenoguanine
(1,N2-EG), show promutagenic properties,
inducing mainly base pair substitutions and a
low level offrameshift mutations (124). Site-
specific mutagenesis studies in Escherichia coli
and in mammalian cell lines have shown that
both EG and £C can induce G:C - A:T
transitions; EC can also lead to C:G - A:T
transversions (125,126). EAcan induce misin-
corporation ofG, C, or A during replication,
thus inducing the base-pair substititions A:T
-* C:G, A:T -* G:C, or A:T -e T:A
(127,128).
7-(2'-Oxoethyl)guanine and three etheno
adducts (-A; £C; and N2,3-EG; Figure 2)
have been detected in DNA from rats and
mice exposed to VC (123,128-131). Highly
variable background levels ofcAand -C were
found in all the tissues examined (132,133).
After exposure of rats to VC, significantly
elevated levels ofsA and EC were measured
in most tissues, except the brain; there were
also no significant increases of EA levels in
the kidney and spleen (121,134).
The liver is one ofthe primary targets for
VC-induced carcinogenesis in rats and
humans. Mutations have been found in liver
tumors associated with VC exposure.
Mutations, all A:T -* T:A transversions, have
been described in the p53 gene in three
human ASL cases (Table 8). In human ASL,
the Ki-rasgene is also activated through a G:C
-- A:T mutation at base 2 ofcodon 13 (Table
9). Ki-ras gene activation has not been found
in rat ASL (141,142). However, 44% of rat
ASL cases were found to contain a mutated
p53 gene: most mutations were base pair sub-
stitutions that involved mainly A:T base pairs
(137). The data suggest the existence of hot
spots for mutations in the p53 gene; one
mutation found in two rat ASL cases was
equivalent to the same mutation characterized
in one human ASL case associated with VC
exposure. In rat HCC induced by VC, the
Ha-ras gene is activated through an A:T e
T:Atransversion in codon 61 (Table 9).
The mutation spectra observed in liver
tumors (ASL and/or HCC) that are associ-
ated with VC exposure in humans and rats
are clearly distinct from those observed in
sporadic liver tumors or in hepatic tumors
associated with other exposures. In rats, the
substitution mutations found at A:T base
pairs in the ras and p53 genes are consistent
with the promutagenic properties ofCA and
with the accumulation and persistence ofthis
lesion in hepatic DNA (121). Altogether,
available data suggest that etheno adducts
Table 7. Absolute risk of angiosarcoma ofthe liver per 100,000 ppm-years.a
Cumulative exposure (ppm-years)
Years since first employment < 2,000 2,000-5,999 6,000-9,999 . 10,000
0-19 1.0 6.8 24.4 44.8
20-24 4.7 32.0 115.6 212.5
. 25 6.2 42.2 152.3 280.0
aData from Simonato et al. (113).
* taS. iVI, Md' '>%g fi'' 4 t''r z ' s..
4EXSX S!X ......
Figure 2. Vinyl chloride reactive metabolites and nucleic acid adducts formed from them in vivo ladapted
from Ciroussel et al. (123)].
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could be involved in the initiation ofhepato-
carcinogenesis byVC.
Analysis ofDose Response
VC has been shown to be carcinogenic and
toxic in both oral and inhalation experimental
bioassays, as well as in human epidemiologic
studies. For VC, dose-response analyses have
been based on data ofASL because it is the
most critical and sensitive effect.
The bioassays that have most often been
used as the basis for dose-response analysis
in animals are the rat inhalation studies of
Maltoni et al. (34,35) (involving a wide
range ofexposure levels and a large number
of animals) and the oral studies of Feron et
al. (31) and Til et al. (32,33). Risk evalua-
tions derived from animal data can be com-
pared with human epidemiologic data on
ASL [e.g., Simonato et al. (113)].
Risk Assessment Based on
Human Epidemiologic Data
Simonato et al. (113) performed a regression
analysis from epidemiologic data to assess
the relative risk of liver cancer and ASL in
occupational exposure to VC using the vari-
ables cumulative exposure (ppm-years) and
years since first employment. On the basis of
this regression analysis, Simonato et al. (113)
calculated the absolute risk of ASL per
100,000 (Table 7). For example, for workers
exposed for > 25 years to < 80 ppm (i.e.,
< 2,000 ppm-years), there is a risk of6.2 as
compared to those who are exposed for only
a few years at the same exposure level. At
higher exposure levels (2,000-5,999 ppm-
years), the risk increases to 42.2.
Physiologically Based
Pharmacokinetic Model
In order to perform quantitative risk assess-
ment using animal bioassays, physiologically
based pharmacokinetic models (PBPKs) have
been developed to derive the concentration
ofactive metabolite at the critical target site,
the liver, and to extrapolate this from animals
to humans. The PBPK model should be vali-
dated by taking into account the known
metabolic pathways and by using experimen-
tally determined metabolic constants.
Clewell et al. (143) developed a model in
which the initial metabolism of VC was
hypothesized to occur via two saturable
pathways (one representing high-affinity,
low-capacity oxidation by CYP2E1 and one
representing low-affinity, high-capacity oxi-
dation by other P450 isozymes), producing
CEO as an intermediate product in both
cases. Chloroacetaldehyde (from CEO) was
modeled as the major substrate ofglutathione
conjugation, with a lesser amount ofCEO as
the substrate of glutathione S-epoxide trans-
ferase. The model was similar to that pro-
posed by Chen and Blancato (144) with
regard to number and type ofcompartments,
physiologic parameters, and the assumption
that metabolism ofVC takes place only in the
liver; the authors used partition coefficients
from the literature (145). The metabolic
parameters for the two oxidative pathways
were estimated from gas uptake experiments
(146); in this model, it was assumed that the
reactive VC metabolites further degrade to
carbon dioxide, react with glutathione, or
react with cellular macromolecules. Param-
eters for subsequent metabolism were taken
from the PBPK model for vinylidene chlo-
ride (147).
This PBPK model (143) was used to
predict the total production of reactive
metabolites from VC in the animal bioassays
and in human exposure scenarios. These
measures of internal exposure were then
used in the linearized multistage model
(LMS) (148) to predict the risk associated
Table 8. Comparison of mutation spectra in the p53gene in livertumors in humans and rats.a
No. mutations No. and types
Species Tumor origin /no. of cases of mutations Reference
Humans VC-associated ASL 3/6 3 A:T- T:A (135)
Cells cultured from VC-associated [CAT CTTI] (136)
livertumor (codon 179)
Rats VC-associated ASL 11/25 5 A:T- T:A (137
2A:T G:C
2 A:TT C:G
3G:C-A:T
One 12 base-pair deletion
1 Deletion
HCC 1/8 1 A:T-T:A
&Adapted from Barbin et al. (137)
Table 9. Mutagenesis of rasproto-oncogenes in VC-associated liver tumors in humans and rats.
Tumor Gene No. mutations/ Base pair
Species origin involved Codon no. tumors changes Codon changes References
Human ASL Ki-ras2 13 15/18 G ->A GGC -GAC (138-1401
Rats ASL Ki-ras2 0/10 (141,1421
HCC H-ras 61 5/8 A.T -* T:A A:T T:A (141,142)
with lifetime exposure to VC in air or drink-
ingwater.
Risk Assessments Based on
Animal Studies
Inhalation Exposure Studies
The 95% upper confidence limit for excess
lifetime risk associated with continuous
inhalation of 1 pug/m3 of VC is 8.4 pg/L x
10-5 in the current U.S. Environmental
Protection Agency (U.S. EPA) health effects
assessment summary tables (HEAST) (149),
which are currently being updated. This is
based on the studies of Maltoni et al. (34),
but not using a PBPK model.
Reitz et al. (150) developed a PBPK
model based on the study of Maltoni et al.
(34), but using a single saturable pathway to
predict the measures ofdelivered dose in rats.
Reitz et al. (150) calculated lifetime average
daily doses and fit them to an empirical
dose-response model (a linearized multistage
model). The 95% upper confidence limits
for excess lifetime risk associated with contin-
uous inhalation of 1 pg/m3 VC calculated
from this PBPK-based approach was 5.7 x
10-7. Thus, the value calculated using the
PBPK model differs from the HEAST risk
estimation [8.4 pg/L x 10-5 (149)] by two
orders ofmagnitude.
Reitz et al. (150) then compared their
predictions of ASL incidences in humans
with different exposures to those reported by
Simonato et al. (113). For example, in the
suibgroup that Simonato et at. (113) estimat-
ed to have the lowest exposures (0-2,000
ppm-years), the reported incidence ofASL
was 6.2/100,000 (Table 7). In contrast, Reitz
et al. (150) calculated a maximum likelihood
estimate of 188-736 cases/100,000 for expo-
sures of 500-2,000 ppm-years. Thus, this
risk assessment (150) using a PBPK model
predicted almost two magnitudes more liver
cancer cases than were actually reported.
Oral Exposure Studies
The present HEAST (149), which uses results
from the rat bioassay of Feron et al. (31),
gives a slope factor of 1.9 per mg/kg/day and
an oral unit riskof5.4 pg/Lx 10-5. These val-
ues are based on the U.S. EPA evaluations of
1984 and 1985 for which a PBPK model was
not used. These values are under review and
aresubject to change.
By using results from the rat bioassay of
Til et al. (32) and by applying the linearized
multistage model, the human lifetime expo-
sure for a 10-5 excess risk ofASL was calcu-
lated to be 20 pg/day (151). In this report,
it was assumed that, in humans, the number
of cancers at other sites may equal that of
ASL, so that a correction (factor of 2) for
cancers other than ASL is justified. VC
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concentrations in drinking water of 5 pg/L
were calculated as being associated with
excess risks of 10-5.
Conclusion
VC is a chemical ofinterest in many fields of
study. Workers in some parts of the world
were and may still be exposed to high levels of
VC, although it is a known carcinogen and is
regulated in many countries. Fortunately, it
seems that ASL is correlated with only high
exposures over long periods. Because ASL has
a latency ofapproximately 20 years, mortality
fromASL caused byVC exposure is still to be
expected in the next few years. With further
improvements in industrial hygiene in coun-
tries all over the world, perhaps VC-induced
ASL mortalities will become a phenomenon
ofthe past.
The detection of VC as a degradation
product of some chlorinated solvents is an
indication ofthe intricate problems that may
be attributed to past and future chemical
waste deposits. Progress in remediation
processes should be able, at least in part, to
resolve these problems.
Research into the mechanisms of car-
cinogenesis has been initiated because ASL is
a rare tumor and its occurrence in VC work-
ers can be correlated with estimated VC
exposure. Studies into mutation spectra
observed in rat and human liver tumors
(ASL and/or HCC) have shown that etheno
adducts, in particular 1,1V-ethenoadenine
(-A), have promutagenic properties and are
responsible for substitution mutations found
at A:T base pairs in the rasandp53genes.
Since the 1970s it has been possible to
monitor exposed VC workers and to keep
records ofmortality cases; a large amount of
data is now available for epidemiologic stud-
ies, which are being continually updated.
Using animal studies and various models,
researchers have attempted to predict the risk
of mortality and to extrapolate predictions
from animals to humans. By comparing these
predictions with human ASL mortality
records, current risk assessment methodology
can be validated.
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